AnaptysBio, Inc. (NASDAQ:ANAB) had its price objective raised by Credit Suisse Group from $34.00 to $38.00 in a research note published on Friday morning. The firm currently has an outperform rating on the biotechnology company’s stock.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research raised shares of AnaptysBio from a hold rating to a buy rating and set a $25.00 price target for the company in a research note on Tuesday, August 22nd. Robert W. Baird assumed coverage on shares of AnaptysBio in a research note on Monday, July 10th. They issued an outperform rating and a $36.00 price target for the company. Finally, Stifel Nicolaus boosted their price target on shares of AnaptysBio from $30.00 to $35.00 and gave the stock a buy rating in a research note on Tuesday, May 2nd. Six investment analysts have rated the stock with a buy rating, The stock presently has an average rating of Buy and a consensus price target of $34.50.

AnaptysBio (NASDAQ ANAB) opened at 23.85 on Friday. AnaptysBio has a one year low of $15.17 and a one year high of $30.71. The company’s market capitalization is $485.16 million. The firm has a 50-day moving average of $23.98 and a 200 day moving average of $24.68.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.13) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.29. The company had revenue of $7 million during the quarter, compared to analysts’ expectations of $3.45 million. Equities research analysts predict that AnaptysBio will post ($1.96) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Credit Suisse Group Boosts AnaptysBio, Inc. (ANAB) Price Target to $38.00” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/28/credit-suisse-group-boosts-anaptysbio-inc-anab-price-target-to-38-00.html.

In other AnaptysBio news, major shareholder Ventures Vii L. P. Avalon sold 37,040 shares of the business’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $24.35, for a total value of $901,924.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now directly owns 1,936,604 shares of the company’s stock, valued at approximately $40,862,344.40. The disclosure for this sale can be found here. In the last three months, insiders sold 1,133,940 shares of company stock valued at $24,223,316.

A number of institutional investors have recently added to or reduced their stakes in ANAB. State Street Corp boosted its position in AnaptysBio by 108.8% in the second quarter. State Street Corp now owns 74,833 shares of the biotechnology company’s stock worth $1,791,000 after buying an additional 38,996 shares in the last quarter. DAFNA Capital Management LLC boosted its stake in shares of AnaptysBio by 22.2% in the second quarter. DAFNA Capital Management LLC now owns 5,500 shares of the biotechnology company’s stock worth $132,000 after buying an additional 1,000 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of AnaptysBio during the second quarter worth about $277,000. Vanguard Group Inc. boosted its stake in shares of AnaptysBio by 22.6% in the second quarter. Vanguard Group Inc. now owns 206,031 shares of the biotechnology company’s stock worth $4,931,000 after buying an additional 37,932 shares during the period. Finally, Northern Trust Corp boosted its stake in shares of AnaptysBio by 360.6% in the second quarter. Northern Trust Corp now owns 60,042 shares of the biotechnology company’s stock worth $1,436,000 after buying an additional 47,005 shares during the period. 71.35% of the stock is owned by institutional investors and hedge funds.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Analyst Recommendations for AnaptysBio (NASDAQ:ANAB)

Receive News & Stock Ratings for AnaptysBio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio Inc. and related stocks with our FREE daily email newsletter.